Core Insights - Cybin Inc. is positioned as a leader in developing next-generation psychedelic-based therapeutics, focusing on major depressive disorder (MDD) and generalized anxiety disorder (GAD) [1][2] - The company has made significant advancements in fiscal 2024, supported by innovative research programs and strong financial health [1][12] - Cybin's proprietary compounds, CYB003 and CYB004, are in advanced clinical stages, with CYB003 receiving Breakthrough Therapy Designation from the FDA [8][10] Financial Performance - As of March 31, 2024, Cybin reported cash reserves of C$209 million (approximately USD$153 million) [12] - The company has access to over C$285 million (about USD$208 million) to support its clinical programs and operational initiatives [12][13] - Zacks Investment Research upgraded Cybin to a Zacks Rank 2 (Buy), indicating a positive outlook based on earnings estimates [6][15] Clinical Developments - Cybin is preparing to launch a Phase 3 multinational study of CYB003 in summer 2024, which aims to evaluate its safety and efficacy in a larger MDD patient population [9][20] - The Phase 2 study of CYB003 showed a mean reduction of 14 points in the MADRS score, indicating significant improvement in depressive symptoms [16] - CYB004 is advancing to a Phase 2 study targeting GAD, with the FDA clearing its Investigational New Drug application [10][17] Insider Confidence - Recent insider transactions indicate strong confidence from executives and directors in Cybin's strategic direction, with substantial stock purchases made by senior officers [4][5] - Notable purchases include 200,000 shares by CEO Douglas Drysdale and other significant acquisitions by senior officers [4] Intellectual Property - Cybin has a robust intellectual property portfolio with over 60 granted patents and more than 200 pending applications, ensuring exclusivity for its treatment candidates until at least 2041 [11]

Core Viewpoint - Cybin Inc. (CYBN) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [3][5]. Earnings Estimates and Stock Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [6]. Cybin Inc. Specifics - For the fiscal year ending March 2025, Cybin Inc. is expected to earn -$0.09 per share, reflecting a 52.6% change from the previous year's reported number [10]. - Over the past three months, the Zacks Consensus Estimate for Cybin Inc. has increased by 15%, indicating positive sentiment among analysts [10]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating [11][13]. - Stocks rated Zacks Rank 1 (Strong Buy) have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the rating system [9].

Core Viewpoint - Cybin Inc. (CYBN) is experiencing a significant downtrend with a 17.5% decline over the past four weeks, but it is now considered oversold, indicating a potential for a price rebound due to strong analyst support for improved earnings estimates [2][3]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for CYBN is currently at 20.85, suggesting that the heavy selling pressure may be exhausting, which could lead to a price bounce back [5]. - A stock is typically deemed oversold when its RSI falls below 30, indicating a potential reversal point [5]. Group 2: Analyst Sentiment - There has been a strong consensus among sell-side analysts regarding CYBN's ability to report better earnings, leading to a 5.6% increase in the consensus EPS estimate over the last 30 days [2]. - CYBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [2].

● . ● Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder May 30, 2024 9:08 AM EDT | Source: Numinus Wellness Inc. Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - In a significant stride towards transforming mental health care, Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) has proudly announced that its research site, Cedar Clinical Research (CCR), has been selected for Cybin's Phase 3 pivotal multinational clinical tria ...

Cybin Inc.’s (CYBN) shares were up 7.2% on Mar 15 after the company initiated a phase II proof-of-concept study evaluating its proprietary deuterated dimethyltryptamine molecule, CYB004, for the treatment of patients with generalized anxiety disorder (GAD).Per the company, the double-blind phase II CYB004-002 study will investigate the safety and efficacy of CYB004 in the given patient population. Patients will be divided into two groups. The first group of patients will receive two IM doses of CYB004, whil ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief Executive Officer of Cybin will participate in a fireside chat at the event and will be available to mee ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary DMT molecule in development for the treatment of GAD. In January 2024, the U.S. Food and Drug Administration (“FDA”) cleared Cybin’s Investig ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder (“MDD”). This program will be the first ever adjunctive Phase 3 deut ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the FDA has granted BTD to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD. If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-bas ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8:30 a.m. ET on Wednesday, March 13, 2024. The Company will provide a program update on CYB003, its proprietary deuterated psilocybin analog in development for the adj ...